You are here

29-06-2018 | © Anatomy Insider, Shutterstock

Organoids in the fight against cancer

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths. European researchers developed novel ex vivo three-dimensional organoid cultures that replicate genetic events in CRC, as tools to test novel therapeutics.

01-04-2017 | © picture

Frontier science and business that makes a difference

Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.

Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."

12-07-2016 | Researcher picture ©Olga NAGY

Evolution of species: different, but not so different

Through her work with the fruit fly Drosophila santomea, Dr Virginie Orgogozo aims to answer one of the most challenging questions of modern evolutionary biology: how do observable characteristics change between species and yet remain stable in a given species?

29-06-2016 | © picture

Stem cells: from frontier research project to promising spin-off company

Haematopoietic Stem Cells (HSCs) are blood cells located in the bone marrow. These cells are extensively used in research to develop treatments for many severe diseases, including HIV and multiple sclerosis, and their transplant is a key therapy for certain types of cancer like leukemia and multiple myeloma. However, the use of HSCs is seriously constrained by their limited availability since growing them in the lab does not produce very large quantities. There is therefore an urgent need for methods allowing scientists to multiply HSCs, without losing any of their properties.

10-11-2015 | Image:©Takashi Ishiuchi & Maria-Elena Torres-Padilla

An international career to push the frontiers of epigenetics

With her degree in biology, Dr Maria-Elena Torres-Padilla left Mexico and embarked on an international career in epigenetics. She completed her PhD at the Pasteur Institute in Paris and then moved to Cambridge University. In 2006 she joined IGBMC in Strasbourg working as a group leader. She has just been appointed Director of the Institute of Epigenetics and Stem Cells of the Helmholtz Zentrum in Munich. Supported by an ERC grant, she studies the mechanisms controlling embryonic cellular plasticity with the aim of shedding new light on today's fertility issues. In this interview she shares her story as a non-European scientist in Europe.